Akero Therapeutics (AKRO) News Today $53.61 -0.19 (-0.35%) Closing price 10/22/2025 04:00 PM EasternExtended Trading$53.60 -0.01 (-0.02%) As of 10/22/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Recommendation of "Hold" from AnalystsOctober 22 at 2:31 AM | marketbeat.comMy Top 3 Pharma StocksOctober 20 at 12:12 PM | seekingalpha.comAssessing Akero Therapeutics (AKRO) Valuation After Strong Share Price GainsOctober 19, 2025 | finance.yahoo.comAkero Therapeutics, Inc. $AKRO Shares Sold by TD Asset Management IncOctober 19, 2025 | marketbeat.comAndrew Cheng Sells 30,000 Shares of Akero Therapeutics (NASDAQ:AKRO) StockOctober 15, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 SharesOctober 15, 2025 | insidertrades.comAkero Therapeutics, Inc. $AKRO Stake Trimmed by Aberdeen Group plcOctober 14, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Cut to "Hold" at HC WainwrightOctober 13, 2025 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Cut to Hold at Wolfe ResearchOctober 13, 2025 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading Volume - Should You Buy?October 11, 2025 | marketbeat.comAkero Therapeutics Acquired by Novo Nordisk for $5.2BOctober 11, 2025 | theglobeandmail.comAkero Therapeutics' (AKRO) Peer Perform Rating Reiterated at Wolfe ResearchOctober 11, 2025 | marketbeat.comLifesci Capital Downgrades Akero Therapeutics (NASDAQ:AKRO) to HoldOctober 11, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Lowered to "Hold" Rating by HC WainwrightOctober 11, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Lowered to "Sell" Rating by Wall Street ZenOctober 11, 2025 | marketbeat.comAkero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero ...October 10, 2025 | theglobeandmail.comWolfe Research Downgrades Akero Therapeutics (AKRO)October 10, 2025 | msn.comAkero Therapeutics (NASDAQ:AKRO) Insider Sells $576,000.00 in StockOctober 10, 2025 | marketbeat.comAkero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKROOctober 10, 2025 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)October 10, 2025 | globenewswire.comAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up - Should You Buy?October 10, 2025 | marketbeat.comAkero Therapeutics' (AKRO) "Hold" Rating Reaffirmed at Jefferies Financial GroupOctober 10, 2025 | marketbeat.comCanaccord Genuity Group Reiterates "Hold" Rating for Akero Therapeutics (NASDAQ:AKRO)October 10, 2025 | marketbeat.comAkero: Novo Nordisk Acquisition Puts Focus On Unprecedented MASH Data With EFXOctober 10, 2025 | seekingalpha.comAkero Therapeutics (NASDAQ:AKRO) Insider Timothy Rolph Sells 12,500 SharesOctober 10, 2025 | insidertrades.comAkero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk MergerOctober 9, 2025 | insidermonkey.comTop Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and MoreOctober 9, 2025 | investopedia.comNovo Nordisk’s liver deal misses bigger ailmentOctober 9, 2025 | reuters.comShareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersOctober 9, 2025 | prnewswire.comNovo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2BOctober 9, 2025 | proactiveinvestors.comAKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to ShareholdersOctober 9, 2025 | businesswire.comAkero Therapeutics Stock Soars on Novo Nordisk Deal.October 9, 2025 | barrons.comAkero Therapeutics soars on $5.2 billion acquisition deal with Novo NordiskOctober 9, 2025 | msn.comNovo Nordisk To Buy Akero Therapeutics for $4.7 BillionOctober 9, 2025 | wsj.comAkero Therapeutics to be Acquired by Novo Nordisk for $5.2 Billion, Offering Shareholders $54 Per Share in CashOctober 9, 2025 | quiverquant.comQNovo Nordisk buys Akero Therapeutics in the USOctober 9, 2025 | reuters.comAkero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 BillionOctober 9, 2025 | globenewswire.comAI-Driven MASH Data from Phase 2b Trials Might Change The Case For Investing In Akero Therapeutics (AKRO)October 9, 2025 | finance.yahoo.comWeiss Ratings Reaffirms Sell (D-) Rating for Akero Therapeutics (NASDAQ:AKRO)October 8, 2025 | marketbeat.comAkero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025October 7, 2025 | globenewswire.comInsider Selling: Akero Therapeutics (NASDAQ:AKRO) COO Sells 12,500 Shares of StockOctober 4, 2025 | insidertrades.comAkero Therapeutics (NASDAQ:AKRO) Stock Rating Upgraded by Wall Street ZenOctober 3, 2025 | marketbeat.comJonathan Young Sells 12,500 Shares of Akero Therapeutics (NASDAQ:AKRO) StockOctober 3, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of "Buy" from BrokeragesSeptember 27, 2025 | marketbeat.com12,600 Shares in Akero Therapeutics, Inc. $AKRO Acquired by Strs OhioSeptember 22, 2025 | marketbeat.comVoya Investment Management LLC Has $3.34 Million Stock Position in Akero Therapeutics, Inc. $AKROSeptember 20, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up - Here's What HappenedSeptember 19, 2025 | marketbeat.comAkero Therapeutics, Inc. $AKRO Shares Acquired by Intech Investment Management LLCSeptember 17, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Insider Timothy Rolph Sells 553 SharesSeptember 13, 2025 | insidertrades.comAkero Therapeutics, Inc. $AKRO Shares Purchased by Woodline Partners LPSeptember 13, 2025 | marketbeat.com Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼1.490.52▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼49▲AKRO Articles Average Week Get the Latest News and Ratings for AKRO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Akero Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Summit Therapeutics News Ascendis Pharma A/S News Dr. Reddy's Laboratories News Viatris News Roivant Sciences News QIAGEN News Elanco Animal Health News BridgeBio Pharma News Moderna News Revolution Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts